| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444641 | European Journal of Cancer | 2013 | 6 Pages |
Abstract
These results demonstrate that the potency and specificity of sildenafil as an inhibitor of ABCB1 and ABCG2 is not sufficient to warrant further clinical testing of this agent in combination with anticancer drugs.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Fan Lin, Lisette Hoogendijk, Levi Buil, Jos H. Beijnen, Olaf van Tellingen,